As revealed by the promoter methylation status chart, HJURP was hypomethylated in bladder urothelial carcinoma, renal papillary cell carcinoma, hepatocellular carcinoma, prostate cancer and testicular germ cell carcinoma, etc. (Fig. 3A–E). Here, HJURP is linked to prostate carcinoma.